Author information:
(1)From the Department of Neurology (A.B.-O.), Perelman School of Medicine, 
University of Pennsylvania, Philadelphia; Neuroimmunology Unit (A.B.-O.), 
Montreal Neurological Institute and Hospital, McGill University and McGill 
University Health Center, Quebec, Canada; Neurosciences Clinical Statistics 
(R.A.G.), Clinical Pharmacology (R.A.G., D.J.A.), and Modeling and Simulation 
(D.J.A.), GlaxoSmithKline, Uxbridge, Middlesex, UK; Neurosciences Therapy Area 
Unit (J.M.T., S.A.V., E.W.L., F.J.D., M.C.L., S.T.K.), SAVM (F.J.D., M.C.L.), 
Global Clinical Safety and Pharmacovigilance (E.W.L.), and Neurosciences 
Clinical Statistics (SecTK), GlaxoSmithKline, Research Triangle Park, NC; 
Department of Neurology (A.E.M.), Corinne Goldsmith Dickinson Center for 
Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY; and 
Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, University 
of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Dr. Derosier is now at 
Clinical Development, Isis Pharmaceutical, Carlsbad, CA. amitbar@upenn.edu.
(2)From the Department of Neurology (A.B.-O.), Perelman School of Medicine, 
University of Pennsylvania, Philadelphia; Neuroimmunology Unit (A.B.-O.), 
Montreal Neurological Institute and Hospital, McGill University and McGill 
University Health Center, Quebec, Canada; Neurosciences Clinical Statistics 
(R.A.G.), Clinical Pharmacology (R.A.G., D.J.A.), and Modeling and Simulation 
(D.J.A.), GlaxoSmithKline, Uxbridge, Middlesex, UK; Neurosciences Therapy Area 
Unit (J.M.T., S.A.V., E.W.L., F.J.D., M.C.L., S.T.K.), SAVM (F.J.D., M.C.L.), 
Global Clinical Safety and Pharmacovigilance (E.W.L.), and Neurosciences 
Clinical Statistics (SecTK), GlaxoSmithKline, Research Triangle Park, NC; 
Department of Neurology (A.E.M.), Corinne Goldsmith Dickinson Center for 
Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY; and 
Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, University 
of Copenhagen, Rigshospitalet, Copenhagen, Denmark. Dr. Derosier is now at 
Clinical Development, Isis Pharmaceutical, Carlsbad, CA.